Ole Jannik Bjerrum

Ole Jannik Bjerrum

Professor, emeritus

ORCID: 0000-0002-1085-8444

Publication year:
All
1 - 10 out of 92Page size: 10
Sort by: Title
  1. Published

    A Paradigm Shift Towards Patient Involvement in Medicines Development and Regulatory Science: Workshop Proceedings and Commentary

    Borup, G., Bach, K. F., Schmiegelow, M., Kildemoes, H. W., Bjerrum, Ole Jannik & Westergaard, N., May 2016, In: Therapeutic Innovation & Regulatory Science. 50, 3, p. 304-311 8 p.

    Research output: Contribution to journal › Comment/debate › Research › peer-review

  2. Published

    A novel inhibitor of advanced glycation end- product formation inhibits mesenteric vascular hypertrophy in experimental diabetes

    Bjerrum, Ole Jannik, 1999, In: Diabetologica. 42, p. 472-479 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    A simple method for the preparation and purification of C1 complement cleaved beta 2-microglobulin from human serum.

    Nissen, Mogens Holst, Johansen, B. & Bjerrum, Ole Jannik, 1997, In: Journal of Immunological Methods. 205, 1, p. 29-33 4 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Alleviation of nociception in rats by treatment with ceftriaxone, a ß-lactam that promote the expression of the excitatory amino acid transporter 2

    Bjerrum, Ole Jannik, Abrahamsen, B. & Honoré, P. G. H., Nov 2011.

    Research output: Contribution to conference › Poster › Communication

  5. Published

    An analysis of the fixed-dose combinations authorized by the European Union, 2009-14: A Focus on benefit-risk and clinial development condition

    Sawicki-Wrzask, D., Thomsen, M. & Bjerrum, Ole Jannik, 2015, In: Therapeutic Innovation & Regulatory Science. 49, 4, p. 553-559 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Analysis of the Authorized Target Populations for Fixed Dose Combination Products Between 2000 and 2017 Reveals Discrepancies Between EMA's and FDA's Views on Initial Dual-Therapy

    Bjerrum, Ole Jannik, Eichendorff, S. & Alkis, N. B., Mar 2020, In: Therapeutic Innovation & Regulatory Science. 54, 2, p. 297-302 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Analysis of the Authorized Target Populations for Fixed Dose Combination Products Between 2000 and 2017 Reveals Discrepancies Between EMA’s and FDA’s Views on Initial Dual-Therapy

    Bjerrum, Ole Jannik, Eichendorff, S. & Alkis, N. B., 2019, In: Therapeutic Innovation & Regulatory Science. 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  8. Published

    Beta-lactam antibiotic as dose dependent analgesic treatment of neuropathic pain

    Bjerrum, Ole Jannik, Abrahamsen, B. & Honoré, P. G. H., 2011.

    Research output: Contribution to conference › Poster › Research › peer-review

  9. Published

    Bivirkningsmonitorering af lægemidler: en ny udfordring af apoteksfarmaceuter

    Christensen, S. T. & Bjerrum, Ole Jannik, 2009, In: Lægemiddelforskning. p. 49-51

    Research output: Contribution to journal › Journal article › Communication

  10. Published

    Blå medicin mod smerter

    Boulakou, A., Bjerrum, Ole Jannik & Honoré, P. G. H., 2012, In: Lægemiddelforskning. 2012, p. 18-19 2 p.

    Research output: Contribution to journal › Journal article › Communication

Previous 1 2 3 4 5 6 7 8 ...10 Next

ID: 1302721